William Blair lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a market ...

Fintel reports that on March 10, 2025, Guggenheim downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Buy ...

Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...

About Neumora Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way ...

Guggenheim lowered shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from a buy rating to a neutral rating in a research note released on Friday morning, Marketbeat.com reports.

William Blair downgraded Neumora Therapeutics (NMRA) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: ...

After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

Neumora Therapeutics (NASDAQ:NMRA) stock drops 11% as Stifel downgrades nothing that J&J (JNJ) discontinues a drug similar to NMRA's lead asset. Read more here.

NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

March 03, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs ...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...